Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Pulmonary hypertension is a complex disease with multiple causes, corresponding to
phenotypic heterogeneity and variable therapeutic responses. Advancing understanding of …

Rationale: Inflammation drives pulmonary arterial hypertension (PAH). Gut dysbiosis causes
immune dysregulation and systemic inflammation by altering circulating microbial …

Pulmonary arterial hypertension (PAH) is a chronic cardiopulmonary syndrome with high
pulmonary vascular load and eventually causing RV heart failure even death. However, the …

The definition of pulmonary hypertension (PH) has changed recently based, in part, on
contemporary outcome data and to focus on early disease detection. Now, PH includes …

Serotonin plays a key role in the development and maintenance of the pathobiology
associated with pulmonary arterial hypertension (PAH). Platelet‐driven and locally produced …

Pulmonary hypertension (PH) is a chronic and fatal disease, for which new therapeutic
drugs and approaches are needed urgently. Baicalein and baicalin, the active compounds …

Pulmonary arterial hypertension (PAH) is a rare disease characterized by high blood
pressure in the pulmonary circulation driven by pathological remodeling of distal pulmonary …

Bone morphogenetic proteins (BMPs) are secretory proteins belonging to the transforming
growth factor-β (TGF-β) superfamily. These proteins play important roles in embryogenesis …

Abstract Background Circular RNAs (circRNAs), a novel class of non-coding RNAs, play an
important regulatory role in pulmonary arterial hypertension (PAH); however, the specific …